Navigation Links
Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
Date:11/14/2011

BASKING RIDGE, N.J., Nov. 14, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announces one poster presentation and two oral presentations at the American Heart Association (AHA) Scientific Sessions meeting on November 14, 2011 during the 9:00 a.m. – 5:00 p.m. EST session.  All three presentations highlight results from Regado's pipeline of antithrombotic agents for the treatment of cardiovascular disease.

Ingo Ahrens, M.D., of University Hospital in Freiburg, Germany, presented "REG1, a Novel RNA-Aptamer Direct Factor IXa-inhibitor Reduces Platelet Activation in Healthy Volunteers and Residual Platelet Aggregation in Patients with ACS.  A RADAR Substudy," at 10:45 a.m. EST.  John Vavalle, M.D., a Fellow in the Division of Cardiology at the Duke University Medical Center, presented further RADAR substudy results in an Abstract Oral Session at 11:15 a.m. EST with a poster titled "The REG1 Anticoagulation System Allows for Early Arterial Sheath Removal After Cardiac Catheterization Without Increases in Time to Hemostasis or Bleeding Complications: An Analysis From the RADAR Clinical Trial."

The above referenced presentations offer substudy analyses of the Company's Phase 2b RADAR clinical trial of REG1, Regado's proprietary anticoagulation system.  The RADAR results demonstrated that REG1 provided nearly complete Factor IXa inhibition with a dose of 1 mg/kg of pegnivacogin and, when followed by 75% and 100% reversal doses of anivamersen, resulted in numerically lower rates of ischemic events when compared with heparin.  The RADAR results clearly support the progression of the development of REG1 to phase 3.   

Dr. Vavalle also presented "Thrombin Generation Kinetics of the REG2 Anticoagulation System: A First-in-Human Experience" at 3 p.m. EST during an Abstract Poster Session. REG2 is Regado's se
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
2. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
3. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
10. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
11. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)... 23, 2014 ResMed (NYSE: RMD ) ... against Chinese medical device manufacturer BMC Medical Co., Ltd. ... BMC,s masks listed below infringe ResMed,s patents, and entered an ... in the United States : ... , Willow nasal pillows mask , iVolve full ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress ... other special occasion outfits, unveils 65 new bridesmaid ... at discounted prices, up to 80% off. , Yunx.co.uk’s ... their fashionable designs, gorgeous looks and delicate craftsmanship. These ... is devoted to designing and offering high-quality women’s dresses ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, ... from sex for one year will be allowed to donate blood ... reverse a 31-year ban on donations from men who have sex ... its intention to release a new draft guidance in early 2015 ... men. The FDA is changing its policy based on data ...
(Date:12/24/2014)... News) -- Adults who experienced childhood abuse or ... suggests a study published online Dec. 24 in ... can have long-lasting effects, like associated medical and ... Dawn Buse, director of behavioral medicine at Montefiore ... a journal news release. "When managing patients ...
(Date:12/24/2014)... Steven Reinberg HealthDay ... New guidelines from the American Diabetes Association (ADA) call for ... with diabetes to help prevent heart disease. These new ... of Cardiology and American Heart Association, which also recommend giving ... heart disease, including people with diabetes. "We agree that ...
(Date:12/24/2014)... 24, 2014 Dr. Svetlana Gomer, MGS ... the nation gathered with US Marines on November 14, ... funds for the Toys for Tots Literacy Program. ... of new books and audio books for the Toys ... children this Christmas. It represents another major strike in ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... , , WASHINGTON, Dec. 14 ... Campaign for Tobacco-Free Kids: , (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ... by the National Institute of Drug Abuse shows that ... youth smoking, but declines have slowed significantly compared to ...
... Only about one in 2,000 people in the United States ... unfortunate few. Ms. Wilcox,s tumor was a classic case. She ... for blocked sinuses. "For several months, I could not breathe ... Goldthwaite, a town of less than 2,000 in the heart of ...
... The study, led by Dr. Shiela Strauss, Associate Professor ... Management Core for NYU,s Colleges of Dentistry and Nursing, ... National Health and Nutrition Examination Survey who had not ... National Center for Health Statistics of the Centers for ...
... a number of medication-related problems, including under treatment, suboptimal ... effects on their quality of life. Now new research ... the University of North Carolina at Chapel Hill shows ... non-adherence to medical regimens is a particular issue for ...
... thistle appears to reduce liver inflammation in cancer patients, ... A medicinal herb, milk thistle, appears to reduce liver ... Chemo drugs often cause liver inflammation, making it necessary ... inflammation subsides. These interruptions in therapy can make treatment ...
... ... by Novartis Oncology, was conducted independently for CURE magazine among 1,365 of its ... their needs. The Leukemia and Lymphoma Society, the National Organization for Rare Disorders, ... in videos which are included at the bottom of this release. , ...
Cached Medicine News:Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 2Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 3Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 4Health News:New Survey Shows Slow Decline in Youth Smoking, Troubling Increase in Smokeless Tobacco Use - Congress, States Must Step Up Tobacco Prevention Efforts 5Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2Health News:Study finds over 90 percent of people with gum disease are at risk for diabetes 2Health News:Racial differences in medication use 2Health News:Herb May Counter Liver Damage From Chemo 2Health News:Herb May Counter Liver Damage From Chemo 3Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 2Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 3Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 4Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 5
Medium clip size, 10mm...
... in 10mm and 5mm sizes. Our market-leading ... placement., ,The LIGACLIP ERCA Endoscopic Rotating ... patient use instrument designed to provide a ... The instrument delivers 20 titanium clips that ...
... utilizes turbidimetric immunoassay methodology which is a ... of 0.2-28.0 mg/dL. This assay is homogeneous, ... clinical chemistry analyzers. The Wako CRP-HS assay ... linearity, correlation, and sensitivity. Expected values are ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: